MedTrace Logo

A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis

NCT07260669 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 190

Last updated 2026-04-17

No results posted yet for this study

Summary

The main objective of the trial is to evaluate the efficacy of vipoglanstat on endometriosis-related non-menstrual pelvic pain (NMPP).

Conditions

  • Endometriosis

Interventions

DRUG

Vipoglanstat

Participants will receive vipoglanstat capsules orally for approximately 4 menstrual cycles during the treatment period.

DRUG

Placebo

Participants will receive matching placebo capsules orally for approximately 4 menstrual cycles during the treatment period.

Sponsors & Collaborators

  • Gesynta Pharma AB

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
44 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-15
Primary Completion
2027-06-30
Completion
2027-06-30

Countries

  • Bulgaria
  • Czechia
  • Hungary
  • Italy
  • Poland
  • Romania
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07260669 on ClinicalTrials.gov